HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.

Abstract
As multiple myeloma tumors universally dysregulate cyclin D genes we conducted high-throughput chemical library screens for compounds that induce suppression of cyclin D2 promoter transcription. The top-ranked compound was a natural triterpenoid, pristimerin. Strikingly, the early transcriptional response of cells treated with pristimerin closely resembles cellular responses elicited by proteosome inhibitors, with rapid induction of heat shock proteins, activating transcription factor 3 (ATF3), and CHOP. Enzymatic assays and immunoblotting confirm that pristimerin rapidly (< 90 minutes) and specifically inhibits chymotrypsin-like proteosome activity at low concentrations (< 100 nM) and causes accumulation of cellular ubiquitinated proteins. Notably, cytotoxic triterpenoids including pristimerin inhibit NF-kappaB activation via inhibition of IKK alpha or IKK beta, whereas proteosome inhibitors instead suppress NF-kappaB function by impairing degradation of ubiquitinated I kappaB. By inhibiting both IKK and the proteosome, pristimerin causes overt suppression of constitutive NF-kappaB activity in myeloma cells that may mediate its suppression of cyclin D. Multiple myeloma is exquisitely sensitive to proteosome or NF-kappaB pathway inhibition. Consistent with this, pristimerin is potently and selectively lethal to primary myeloma cells (IC(50) < 100 nM), inhibits xenografted plasmacytoma tumors in mice, and is synergistically cytotoxic with bortezomib--providing the rationale for pharmaceutical development of triterpenoid dual-function proteosome/NF-kappaB inhibitors as therapeutics for human multiple myeloma and related malignancies.
AuthorsRodger E Tiedemann, Jessica Schmidt, Jonathan J Keats, Chang-Xin Shi, Yuan Xiao Zhu, Stephen E Palmer, Xinliang Mao, Aaron D Schimmer, A Keith Stewart
JournalBlood (Blood) Vol. 113 Issue 17 Pg. 4027-37 (Apr 23 2009) ISSN: 1528-0020 [Electronic] United States
PMID19096011 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Biological Products
  • Cyclin D
  • Cyclins
  • NF-kappa B
  • Pentacyclic Triterpenes
  • Proteasome Inhibitors
  • Triterpenes
  • Chymases
  • Proteasome Endopeptidase Complex
  • celastrol
Topics
  • Animals
  • Antineoplastic Agents (chemistry, pharmacology)
  • Apoptosis (drug effects)
  • Biological Products (chemistry, pharmacology)
  • Bone Marrow Cells (cytology, drug effects)
  • Cell Lineage
  • Cells, Cultured
  • Chymases (antagonists & inhibitors, metabolism)
  • Coculture Techniques
  • Combinatorial Chemistry Techniques
  • Cyclin D
  • Cyclins (genetics, metabolism)
  • Drug Screening Assays, Antitumor
  • Enzyme Activation (drug effects)
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Mice
  • Molecular Structure
  • Multiple Myeloma (metabolism, pathology)
  • NF-kappa B (antagonists & inhibitors, metabolism)
  • Pentacyclic Triterpenes
  • Proteasome Endopeptidase Complex (metabolism)
  • Proteasome Inhibitors
  • Transcriptional Activation (drug effects)
  • Triterpenes (chemistry, pharmacology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: